> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# AtriCure Posts $4.1 Million Quarterly Profit As Pain Probes Surge And Hybrid Ablation Shrinks
- URL: https://www.bullished.co/atricure-posts-4-1-million-quarterly-profit-as-pain-probes-surge-and-hybrid-ablation-3ef0d577/
- Published: 2026-11-03T22:08:50.000Z
- Updated: 2026-11-03T22:08:50.000Z
- Description: Revenue rose 15.0% to $154.5 million in the third quarter, and the company lifted its full-year revenue outlook.
- Author: Matteo Parrino
- Tags: Earnings, ATRC, Industry: Healthcare

AtriCure, which makes surgical devices for atrial fibrillation, appendage management and post-surgical pain, reported third-quarter net income of [$4.1 million](https://www.sec.gov/Archives/edgar/data/0001323885/000132388526000038/exhibit991-1132026.htm?ref=bullished.co) on Tuesday, against a $267,000 loss a year earlier. Revenue climbed 15.0% to $154.5 million, even as sales of its minimally invasive ablation products fell.

## Pain probes and clips carry the quarter

Revenue growth was 15.1% on a constant-currency basis, the company said in an [8-K](https://www.sec.gov/Archives/edgar/data/0001323885/000132388526000038/atrc-20261103.htm?ref=bullished.co). U.S. revenue rose 17.1% to $128.0 million, an increase of $18.7 million. International revenue rose 5.8% to $26.4 million, with growth in every franchise.

U.S. pain management sales reached $28.1 million from $20.8 million a year earlier. The company credited the cryoSPHERE MAX probe, the EnCompass clamp in open ablation, and the AtriClip FLEX-Mini and PRO-Mini devices for appendage management.

U.S. minimally invasive ablation fell to $5.4 million from $7.4 million. AtriCure attributed the drop to a continued decline in Hybrid procedures as physicians adopt PFA catheters, a competing way of treating Afib.

## Margins widen, profit turns

Gross margin rose 180 basis points, or 1.8 percentage points, to 77.3%, driven mainly by favorable product and geographic mix. Operating income was $4.4 million versus $0.2 million a year earlier, and earnings came to $0.08 per share against a $0.01 loss.

Adjusted EBITDA, the company's earnings measure before interest, taxes, depreciation, stock pay and certain one-time items, reached $26.8 million, up 51% from a year earlier. Adjusted earnings per share were $0.18, versus an adjusted loss of $0.01\. The quarter included $4.5 million of acquired in-process research expense.

CEO Michael Carrel said the results show "the strength of our broad portfolio" and pointed to rapid progress in the BoxX-NoAF clinical trial.

## Outlook and the balance sheet

AtriCure now projects full-year 2026 revenue of about $606 million to $610 million and adjusted EBITDA of about $91 million to $94 million. It expects net income of $0.21 to $0.27 per share, or adjusted earnings of about $0.40 to $0.46, and continued positive cash generation.

Cash stood at $187.0 million at September 30, up from $167.4 million at the end of 2025, against $61.0 million of long-term debt.

Management discusses the results on a call at 4:30 p.m. Eastern on Tuesday, with a webcast replay available for 90 days.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — AtriCure, Inc. (ATRC)](https://www.sec.gov/Archives/edgar/data/0001323885/000132388526000038/atrc-20261103.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit991-1132026.htm — AtriCure, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001323885/000132388526000038/exhibit991-1132026.htm?ref=bullished.co) — SEC EDGAR